Learn about how T cell exhaustion poses a significant challenge in immuno-oncology and the way epigenetic mechanisms can help develop strategies for reinvigorating exhausted T cells.
A study where we have employed orthogonal target validation strategies with 3 orthogonal LOF technologies (CRISPRko, CRISPRi, and siRNA) with genes involved in maintenance of the mesenchymal-to-epithelial transition (MET).
Given the enthusiasm for adopting CRISPR-based approaches, let’s take a look at the known limiting factors in using arrayed lentiviral resources, and what we can learn from this work as CRISPR arrayed screening advances as a discovery method.
Learn about considerations around the development of the Dharmacon™ Edit-R™ CRISPRko algorithm for functional and specific guide RNA
Cell panel screening assays are an essential part of the drug discovery toolbox. However, fully resolving the drug response profiles of slow-acting therapeutics remains challenging with conventional short term assay formats. Elucidation of the effects of these drug candidates, and those that target epigenetic pathways, requires much greater optimization of longer-term assay conditions.
Reliable and consistent quality reagents are critical to experimental success and reproducibility. Learn about how Dharmacon RNA and DNA oligonucleotide synthesis delivers that level of quality, and explore troubleshooting tips for investigating unexpected results in your experiments.
The reasoning and research behind our Dharmacon™ CRISPRi platform recently published in The CRISPR Journal.
Knowing the distinction between "synthesis scale" and "yield" is critical when ordering custom oligos. Here we explain the terms, so you can make sure to get the right amount for your needs.
All you need to know if you're thinking about labeling your custom oligos with fluorophores.
On Wednesday October 19, The Medical Device Innovation Consortium (MDIC) announced its partnership with Horizon Discovery to develop and manufacture somatic reference samples (SRSs) to simplify and support the validation of NGS-based cancer diagnostics.